Anna Kreutzman

List of Publications by Year
in descending order

28 papers	769 citations	516215 16 h-index	580395 25 g-index
31 all docs	31 docs citations	31 times ranked	1042 citing authors

#	Article	IF	Citations
1	T and NK cell abundance defines two distinct subgroups of renal cell carcinoma. OncoImmunology, 2022, 11, 1993042.	2.1	16
2	Spatial immunoprofiling of the intratumoral and peritumoral tissue of renal cell carcinoma patients. Modern Pathology, 2021, 34, 2229-2241.	2.9	25
3	CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia. Biomarker Research, 2020, 8, 54.	2.8	18
4	Somatic mTOR mutation in clonally expanded T lymphocytes associated with chronic graft versus host disease. Nature Communications, 2020, 11, 2246.	5.8	20
5	Novel Hemizygous IL2RG p.(Pro58Ser) Mutation Impairs IL-2 Receptor Complex Expression on Lymphocytes Causing X-Linked Combined Immunodeficiency. Journal of Clinical Immunology, 2020, 40, 503-514.	2.0	11
6	Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients. Cancer Immunology, Immunotherapy, 2020, 69, 717-730.	2.0	18
7	Single-Cell Roadmap of Immune Cell Response in Chronic Myeloid Leukemia. Blood, 2020, 136, 4-5.	0.6	0
8	Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line. OncoImmunology, 2019, 8, e1638210.	2.1	19
9	Immediate Effects of Dasatinib on the Migration and Redistribution of NaÃ¯ve and Memory Lymphocytes Associated With Lymphocytosis in Chronic Myeloid Leukemia Patients. Frontiers in Pharmacology, 2019, 10, 1340.	1.6	11
10	Immune cell phenotype and functional defects in Netherton syndrome. Orphanet Journal of Rare Diseases, 2018, 13, 213.	1.2	22
11	Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1543-1554.	1.2	20
12	Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner. Clinical Cancer Research, 2017, 23, 6697-6707.	3.2	41
13	Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia. PLoS ONE, 2017, 12, e0171041.	1.1	7
14	Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia. Cancer Immunology, Immunotherapy, 2015, 64, 665-676.	2.0	18
15	Enlarged Memory T-Cell Pool and Enhanced Th1-Type Responses in Chronic Myeloid Leukemia Patients Who Have Successfully Discontinued IFN-Î± Monotherapy. PLoS ONE, 2014, 9, e87794.	1.1	41
16	Imatinib and pegylated <scp>IFN</scp>â€Î±2b discontinuation in firstâ€line chronic myeloid leukemia patients following a major molecular response. European Journal of Haematology, 2014, 92, 413-420.	1.1	11
17	IFNÎ± induces prolonged remissions modeling curative immunologic responses in chronic myeloid leukemia. OncoImmunology, 2014, 3, e28781.	2.1	7
18	Dasatinib promotes Th1-type responses in granzyme B expressing T-cells. OncoImmunology, 2014, 3, e28925.	2.1	38

#	Article	IF	Citations
19	CCR7 As a New Biomarker in Graft-Versus-Host Disease: T Cells Expressing the Homing Receptor CCR7 Mediate the Pathogenesis of Gvhd. Blood, 2014, 124, 3930-3930.	0.6	0
20	Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. Leukemia, 2013, 27, 914-924.	3.3	84
21	NK-Cells In Dasatinib-Treated Chronic Myeloid Leukemia Patients Display a Unique Phenotype Associated With Cytotoxic Potential. Blood, 2013, 122, 1475-1475.	0.6	0
22	Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia. Experimental Hematology, 2012, 40, 906-913.e1.	0.2	20
23	Chronic Myeloid Leukemia Patients Undergoing Interferon Alpha Therapy Exhibit Normal Peripheral Blood Gamma Delta T Cells That May Be Expanded in Vitro to Generate Predominantly CD45RA-Positive Effector Memory Cells for Immunotherapy. Blood, 2012, 120, 3729-3729.	0.6	5
24	Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia, 2011, 25, 1587-1597.	3.3	87
25	Chronic Myeloid Leukemia Patients in Prolonged Remission following Interferon-Î± Monotherapy Have Distinct Cytokine and Oligoclonal Lymphocyte Profile. PLoS ONE, 2011, 6, e23022.	1.1	44
26	Poor cytokine-induced phosphorylation in chronic myeloid leukemia patients at diagnosis is effectively reversed by tyrosine kinase inhibitor therapy. Experimental Hematology, 2011, 39, 102-113.e1.	0.2	15
27	Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood, 2010, 116, 772-782.	0.6	168
28	Clonal Expansion of T/NK-Cells during Tyrosine Kinase Inhibitor Dasatinib Therapy. Blood, 2008, 112, 573-573.	0.6	3